Fundraising FoxFluGen
Madison, US · Wisconsin corporation · 3 known investors
Find your way into FluGen
Sign up to see every warm intro you have to FluGen
- Paths you didn't know you had: your email and LinkedIn already hold routes to the FluGen team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
PV
Paul V. RadspinnerFounderPaul V. Radspinner spent 15 years leading international operations and commercialization at Eli Lilly, and held positions in pharmaceutical IP portfolio management at the Wisconsin Alumni Research Foundation and business development at Deltanoid Pharmaceuticals. He is co-founder and CEO of FluGen, a clinical-stage biopharmaceutical company developing an intranasal influenza vaccine platform.
Board
PM
Phillip M. HalpernBoard director
TF
DS
Dan StinchcombBoard director
CB
C. Boyd ClarkeBoard director
DG
David G. WalshBoard director
PW
CH
Craig HeimBoard director
DM
Deven McGlennBoard director
SL
Scott L. KlugBoard director
RR
Russell R. SmestadBoard director
Investors · 3
Venture Managementlisted by Venture ManagementMadison
How we know: Venture Management's portfolio page · Not right? Tell us
Wisconsin Investment Partnerslisted by Wisconsin Investment PartnersMadison · $5K – $100K
How we know: Wisconsin Investment Partners's portfolio page · Not right? Tell us
Clarevia VenturesreportedMadison · $250K – $2.5M
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$33.9M disclosed across 5 rounds · 2014–2020
▶$8.2MraisedMay 2020 · 47 investors · BiotechnologyRule 506(b)
▶$8.2MraisedMay 2020 · 47 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul WeissDirector
- Eric PatzerDirector
- David G. WalshDirector
- Paul V. RadspinnerExecutive Officer, Director
- Erik IversonDirector
- C. Boyd ClarkeDirector
- David NewbergDirector
- Pamuk BilselExecutive Officer
- Offering amount
- $8.5M
- Amount sold
- $8.2M
- First sale
- Apr 2020
- Incorporated
- Corporation, Wisconsin
- Federal exemptions
- 06b
▶$5.6MraisedNov 2018 · 36 investors · BiotechnologyRule 506(b)
▶$5.6MraisedNov 2018 · 36 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Pamuk BilselExecutive Officer
- C. Boyd ClarkeDirector
- Michael WagnerDirector
- Paul WeissDirector
- Phillip M. HalpernDirector
- Paul V. RadspinnerExecutive Officer, Director
- David G. WalshDirector
- Offering amount
- $5.6M
- Amount sold
- $5.6M
- First sale
- Oct 2018
- Incorporated
- Corporation, Wisconsin
- Federal exemptions
- 06b
▶$5.5MraisedAug 2017 · 25 investors · BiotechnologyRule 506(b)
▶$5.5MraisedAug 2017 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael WagnerDirector
- David G. WalshDirector
- Phillip M. HalpernDirector
- Paul V. RadspinnerExecutive Officer, Director
- Dan StinchcombDirector
- Pamuk BilselExecutive Officer
- Paul WeissDirector
- C. Boyd ClarkeDirector
- Offering amount
- $5.5M
- Amount sold
- $5.5M
- First sale
- Jun 2017
- Incorporated
- Corporation, Wisconsin
- Federal exemptions
- 06b
▶$11.4MraisedApr 2017 · 29 investors · BiotechnologyRule 506(b)
▶$11.4MraisedApr 2017 · 29 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dan StinchcombDirector
- C. Boyd ClarkeDirector
- Phillip M. HalpernDirector
- Paul V. RadspinnerExecutive Officer, Director
- David G. WalshDirector
- Pamuk BilselExecutive Officer
- Paul WeissDirector
- Craig HeimDirector
- Offering amount
- $11.4M
- Amount sold
- $11.4M
- First sale
- Aug 2015
- Incorporated
- Corporation, Wisconsin
- Federal exemptions
- 06b
▶$3.2MraisedMay 2014 · 15 investors · BiotechnologyRule 506(b)
▶$3.2MraisedMay 2014 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Pamuk BilselExecutive Officer
- Deven McGlennDirector
- Terence F. KellyDirector
- Scott L. KlugDirector
- David G. WalshDirector
- Russell R. SmestadDirector
- Bryan RenkDirector
- Phillip M. HalpernDirector
- Paul V. RadspinnerExecutive Officer, Director, Promoter
- Offering amount
- $3.9M
- Amount sold
- $3.2M
- First sale
- Feb 2014
- Incorporated
- Corporation, Wisconsin
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as FluGen.
Non-dilutive funding · 6 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $349.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2017 | $1.8M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2015 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2014 | $600K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $220.1K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- Who founded FluGen?
- FluGen was founded by Paul V. Radspinner.
- Who are FluGen's investors?
- FluGen's investors include Venture Management, Wisconsin Investment Partners, Clarevia Ventures.
- How much funding has FluGen raised?
- FluGen has disclosed $33.9M raised across 5 rounds.
- Where is FluGen headquartered?
- FluGen is headquartered in Madison, US.